Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Novo Nordisk has bolstered its pipeline by paying $340 million upfront for rights to an Omeros Corp drug with potential ...

Carol Lefevre stumbled on tai chi while recovering from cancer, and after losing her mother and her aunt. It transformed her ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) ...

Human interleukin-26 (IL-26) is linked to intestinal inflammation and is bactericidal in vitro. This study uses zebrafish as ...

Wildfire smoke causes more air pollution than current atmospheric models can predict. A new study by researchers at King Abdullah University of Science and Technology (KAUST) and the Chinese Academy ...

This is the first in a four-part series. The world is in the early stages of the next industrial revolution: quantum ...

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained ...

Infrastructure experts, government officials, academics, and development practitioners, have stressed the urgent need for Africa to integrate women’s voices in infrastructure delivery, warning that ...